Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

Neurology

Volumn 84, Issue 16, 2015, Pages 1639-1643

  Kuhle, Jens ^a,b   Disanto, Giulio ^a   Lorscheider, Johannes ^b   Stites, Tracy ^c   Chen, Yu ^c   Dahlke, Frank ^c   Francis, Gordon ^c   Shrinivasan, Anupama ^d   Radue, Ernst Wilhelm ^b   Giovannoni, Gavin ^a   Kappos, Ludwig ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Novartis Healthcare Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; LIVER ENZYME; NEUROFILAMENT LIGHT CHAIN; NEUROFILAMENT PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; PLACEBO; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ELISA KIT; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INTERMEDIATE FILAMENT; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE FIBER; NEUROFILAMENT; PATHOLOGY; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AXONS; BIOMARKERS; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERMEDIATE FILAMENTS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROFIBRILS; PLACEBOS; PROPYLENE GLYCOLS; SPHINGOSINE; TREATMENT OUTCOME;

EID: 84928139473     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001491     Document Type: Article

References (10)

1. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005; 233:183-198.
2. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606-616.
3. Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 2013;19:1597-1603.
4. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011;69:83-89.
5. Kuhle J, Malmestrom C, Axelsson M, et al. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013;128:e33-e36.
6. Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010; 176:2682-2694.
7. Kappos L, Radue EW, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
8. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
9. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545-556.
10. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 2013;8:e75091.